Objective
"The human immunodeficiency virus (HIV) continues to be a major public health issue. Current treatments can slow down disease progression, but high costs, severe side effects and the emergence of drug-resistant strains all call for the development of new treatment regimes. The detailed understanding of virus-host interactions is of utmost importance for this endeavor. The cytidine deaminase APOBEC3 (A3) proteins, and in particular APOBEC3G (A3G), are potent host restriction factors that can be packaged into assembling HIV-1 virions and severely compromise viral infectivity. To evade this powerful restriction, HIV-1 relies on the vif (viral infectivity factor) protein, which has evolved to promote proteasome-dependent A3G degradation. Despite intensive research and the high potential of the vif-A3G axis for therapeutic intervention, the precise mechanisms of A3G packaging and HIV inhibition are not fully understood. As a polynucleotide editing enzyme, A3G induces hypermutation in the viral genomic DNA. Additionally, it has recently become evident that A3G also interferes with the process of reverse transcription in a deaminase-independent way. The research proposed here is designed to elucidate the molecular basis of A3G-mediated inhibition of cDNA synthesis during reverse transcription using a combination of experimental approaches and systems. This involves: 1) The assessment of reverse transcription efficiency in the presence and absence of A3 proteins in vitro as well as in physiologically relevant human CD4+ T cells. Importantly, this will include a novel assay designed to map 3’ termini of nascent viral cDNA products. 2) Mapping of A3G binding sites on viral genomic RNA and identification cellular RNA binding partners using CLIP (crosslinking and immunoprecipitation) assays. 3) A detailed investigation of A3G’s interaction with components of the reverse transcription complex (RTC)."
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- natural sciences biological sciences genetics RNA
- natural sciences biological sciences biochemistry biomolecules proteins enzymes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2012-IIF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
WC2R 2LS London
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.